Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$5.37 +3.1%	$4.71	$3.42 ▼ $7.20	$301.87M	1.94	1.52 million shs	457,421 shs
CDTX Cidara Therapeutics	$23.30 +2.8%	$20.81	$10.14 ▼ $28.42	$292.35M	0.86	80,641 shs	78,993 shs
CYRX Cryoport	$5.84 +8.1%	$5.90	$4.58 ▼ $11.64	$292.80M	1.92	537,631 shs	415,461 shs
TCRX TScan Therapeutics	$1.75 +19.9%	$1.38	$1.02 ▼ $9.29	$99.03M	1.06	408,751 shs	1.18 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	+3.07%	-1.83%	+10.95%	+6.76%	-10.65%
CDTX Cidara Therapeutics	+2.78%	-2.92%	+7.42%	-0.85%	+87.75%
CYRX Cryoport	+8.15%	-3.15%	-0.34%	-11.65%	-43.25%
TCRX TScan Therapeutics	+19.86%	+22.38%	+9.37%	-8.85%	-79.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACB Aurora Cannabis	0.5083 of 5 stars	0.0	2.0	0.0	2.5	0.8	0.6
CDTX Cidara Therapeutics	4.3448 of 5 stars	4.6	3.0	4.6	2.2	0.8	0.0
CYRX Cryoport	3.0644 of 5 stars	4.4	1.0	0.0	2.7	2.5	0.6
TCRX TScan Therapeutics	3.5038 of 5 stars	4.5	1.0	0.0	3.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	3.67	Strong Buy	N/A	N/A
CDTX Cidara Therapeutics	3.22	Buy	$42.00	80.26% Upside
CYRX Cryoport	2.71	Moderate Buy	$11.00	88.36% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	345.71% Upside

Current Analyst Ratings Breakdown

Latest TCRX, ACB, CDTX, and CYRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/27/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
5/8/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$320.81M	0.94	$0.20 per share	26.35	$8.18 per share	0.66
CDTX Cidara Therapeutics	$302K	968.03	N/A	N/A	($1.82) per share	-12.80
CYRX Cryoport	$232.13M	1.26	$0.34 per share	16.95	$9.45 per share	0.62
TCRX TScan Therapeutics	$4.42M	22.40	N/A	N/A	$3.15 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$48.62M	$0.05	107.42	12.20	N/A	0.42%	0.59%	0.42%	6/19/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/12/2025 (Estimated)
CYRX Cryoport	-$99.59M	-$2.34	N/A	N/A	N/A	-70.08%	-13.35%	-6.43%	8/5/2025 (Estimated)
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	8/11/2025 (Estimated)

Latest TCRX, ACB, CDTX, and CYRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/19/2025	Q4 2025	ACB Aurora Cannabis	$0.11	N/A	N/A	N/A	$88.85 million	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/7/2025	Q1 2025	CYRX Cryoport	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million
3/4/2025	Q4 2024	CYRX Cryoport	-$0.33	-$0.42	-$0.09	-$0.42	$58.71 million	$59.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX Cryoport	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.07	3.30	1.60
CDTX Cidara Therapeutics	N/A	3.54	3.54
CYRX Cryoport	0.48	5.70	5.32
TCRX TScan Therapeutics	0.13	9.56	9.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
CDTX Cidara Therapeutics	35.82%
CYRX Cryoport	92.90%
TCRX TScan Therapeutics	82.83%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
CDTX Cidara Therapeutics	3.89%
CYRX Cryoport	10.00%
TCRX TScan Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,340	56.21 million	54.85 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
CYRX Cryoport	1,020	50.14 million	44.44 million	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable

TCRX, ACB, CDTX, and CYRX Headlines

Recent News About These Companies

TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update

June 3 at 12:59 PM | marketbeat.com

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

TScan Therapeutics (NASDAQ:TCRX) & Relay Therapeutics (NASDAQ:RLAY) Head to Head Contrast

May 25, 2025 | americanbankingnews.com

Lynx1 Capital Management Lp Acquires 1,200,000 Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock

May 22, 2025 | insidertrades.com

TScan Therapeutics (NASDAQ:TCRX) Announces Quarterly Earnings Results

May 14, 2025 | marketbeat.com

Equities Analysts Set Expectations for TCRX Q2 Earnings

May 13, 2025 | marketbeat.com

Wedbush Equities Analysts Cut Earnings Estimates for TCRX

May 11, 2025 | marketbeat.com

Research Analysts Issue Forecasts for TCRX Q1 Earnings

May 10, 2025 | marketbeat.com

What Analysts Are Saying About TScan Therapeutics Stock

May 10, 2025 | nasdaq.com

HC Wainwright Has Lowered Expectations for TScan Therapeutics (NASDAQ:TCRX) Stock Price

May 9, 2025 | marketbeat.com

TScan Therapeutics' (TCRX) "Outperform" Rating Reiterated at Wedbush

May 8, 2025 | marketbeat.com

3TCRX : What Analysts Are Saying About TScan Therapeutics Stock

May 7, 2025 | benzinga.com

TScan Therapeutics (TCRX) to Release Earnings on Monday

May 7, 2025 | marketbeat.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

May 6, 2025 | zacks.com

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Buy" from Analysts

May 5, 2025 | marketbeat.com

TScan Therapeutics Announces Abstract Acceptance for Poster Presentation at ASGCT 28th Annual Meeting

April 30, 2025 | nasdaq.com

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

April 28, 2025 | globenewswire.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 9.62%

April 17, 2025 | aaii.com

Needham Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

April 9, 2025 | markets.businessinsider.com

Why TScan Therapeutics, Inc.’s (TCRX) Stock Is Up 17.27%

April 8, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, ACB, CDTX, and CYRX Company Descriptions

Aurora Cannabis NASDAQ:ACB

$5.37 +0.16 (+3.07%)

Closing price 06/3/2025 04:00 PM Eastern

Extended Trading

$5.46 +0.09 (+1.77%)

As of 09:19 AM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Cidara Therapeutics NASDAQ:CDTX

$23.30 +0.63 (+2.78%)

Closing price 06/3/2025 04:00 PM Eastern

Extended Trading

$23.53 +0.23 (+0.97%)

As of 09:08 AM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport NASDAQ:CYRX

$5.84 +0.44 (+8.15%)

Closing price 06/3/2025 04:00 PM Eastern

Extended Trading

$5.85 +0.01 (+0.17%)

As of 07:47 AM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

TScan Therapeutics NASDAQ:TCRX

$1.75 +0.29 (+19.86%)

Closing price 06/3/2025 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.57%)

As of 09:01 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time